Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs placebo with ddAC-PacHP in early high-risk HER2-positive breast cancer (neoadjuvant/adjuvant)
CTR20191950Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in breast cancer, sponsored by Roche. Started Dec 2019; status: terminated.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20191950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191950.